Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Br J Haematol
    April 2024
  1. KUHNL A, Roddie C, Kirkwood AA, Chaganti S, et al
    Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
    Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19453.
    >> Share

  2. MARTYNCHYK A, Hawkes EA
    Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
    Br J Haematol. 2024 Apr 6. doi: 10.1111/bjh.19456.
    >> Share

  3. ATALLAH-YUNES SA, Habermann TM, Khurana A
    Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
    Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
    >> Share

  4. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
    Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
    >> Share

  5. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    >> Share

  6. MOULIN C, Beaupain B, Suarez F, Bertrand Y, et al
    CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.
    Br J Haematol. 2024;204:1383-1392.
    >> Share

    March 2024
  7. MERLI M, Costantini A, Tafuri S, Bavaro DF, et al
    Management of vaccinations in patients with non-Hodgkin lymphoma.
    Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19422.
    >> Share

  8. MANOS K, Churilov L, Grigg A, Di Ciaccio P, et al
    Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
    Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407.
    >> Share

  9. BAPTISTA P, Aguiar E, Fonseca E, Pinto R, et al
    Intravascular large B-cell lymphoma presenting with haemophagocytic syndrome.
    Br J Haematol. 2024 Mar 12. doi: 10.1111/bjh.19350.
    >> Share

  10. LI X, Gao F, Meng X, Zhang X, et al
    Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
    Br J Haematol. 2024 Mar 6. doi: 10.1111/bjh.19393.
    >> Share

  11. NGUYEN PC, Nguyen T, Wilson C, Tiong IS, et al
    Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
    Br J Haematol. 2024;204:910-920.
    >> Share

  12. AL-MASHHADI AL, Jakobsen LH, Brown P, Gang AO, et al
    Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
    Br J Haematol. 2024;204:839-848.
    >> Share

    February 2024
  13. BISHTON MJ, Crooks CJ, Card TR, West J, et al
    Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
    Br J Haematol. 2024 Feb 29. doi: 10.1111/bjh.19371.
    >> Share

  14. YE P, Cheng Y, Lian J, Tong H, et al
    Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19367.
    >> Share

  15. STEPANISHYNA Y, Manni M, Civallero M, Shokun N, et al
    Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352.
    >> Share

  16. FLORA DR, Parsons SK, Liu N, Yu KS, et al
    Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19307.
    >> Share

  17. VOGELSBERG A, Harland L, Borgmann V, Otto F, et al
    Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19335.
    >> Share

  18. BEDNARSKA K, Chowdhury R, Tobin JWD, Swain F, et al
    Epstein-Barr virus-associated lymphomas decoded.
    Br J Haematol. 2024;204:415-433.
    >> Share

  19. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    >> Share

  20. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    >> Share

  21. PELLICCIA S, Rogges E, Cardoni A, Lopez G, et al
    The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Br J Haematol. 2024;204:534-547.
    >> Share

    January 2024
  22. LUEDERSEN J, Stadt UZ, Richter J, Oschlies I, et al
    Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
    Br J Haematol. 2024 Jan 26. doi: 10.1111/bjh.19308.
    >> Share

  23. YANG P, Cai M, Cao Y, Fan S, et al
    Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
    Br J Haematol. 2024 Jan 25. doi: 10.1111/bjh.19317.
    >> Share

  24. ABEYAKOON C, Gregory GP
    New standards of care for treatment of diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Jan 22. doi: 10.1111/bjh.19295.
    >> Share

  25. FOX CP, Chaganti S, McIlroy G, Barrington SF, et al
    The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2024 Jan 21. doi: 10.1111/bjh.19273.
    >> Share

  26. LIAPIS K, Misidou C, Spanoudakis E, Kotsianidis I, et al
    Concurrent visceral leishmaniasis and diffuse large B-cell lymphoma of the bone marrow.
    Br J Haematol. 2024 Jan 7. doi: 10.1111/bjh.19283.
    >> Share

  27. WALEWSKA R, Eyre TA, Barrington S, Brady J, et al
    Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
    Br J Haematol. 2024;204:86-107.
    >> Share

  28. VISCO C
    Letting the mantle out of the bag.
    Br J Haematol. 2024;204:11-13.
    >> Share

  29. KHWAJA J, Vos JMI, Pluimers TE, Japzon N, et al
    Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
    Br J Haematol. 2024;204:177-185.
    >> Share

  30. DODERO A, Bramanti S, Di Trani M, Pennisi M, et al
    Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Br J Haematol. 2024;204:151-159.
    >> Share

    December 2023
  31. BAECH J, Husby S, Trab T, Kragholm K, et al
    Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
    Br J Haematol. 2023 Dec 28. doi: 10.1111/bjh.19272.
    >> Share

  32. MOTOMURA Y, Yoshifuji K, Tachibana T, Takase H, et al
    Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
    Br J Haematol. 2023 Dec 22. doi: 10.1111/bjh.19266.
    >> Share

  33. TOTARO A, Calafiore AM, Sacra C, Magnano D, et al
    Huge right atrial mass in mantle cell lymphoma.
    Br J Haematol. 2023 Dec 21. doi: 10.1111/bjh.19258.
    >> Share

  34. JIN X, Zhou W, Jiang H, Chen Z, et al
    A case of a large number of Reed-Sternberg cells in pleural fluid following treatment of classical Hodgkin lymphoma.
    Br J Haematol. 2023 Dec 20. doi: 10.1111/bjh.19260.
    >> Share

  35. MASRONI MSB, Leong SM, Cheng H, Lim GS, et al
    miR-101-5p modulation of CD47 in diffuse large B-cell lymphoma: Implications for anti-CD47 immunotherapy and prognostication.
    Br J Haematol. 2023 Dec 12. doi: 10.1111/bjh.19264.
    >> Share

  36. FLOSPERGHER E, Marino F, Calimeri T, Cangi MG, et al
    Primary central nervous system marginal zone lymphoma.
    Br J Haematol. 2023 Dec 6. doi: 10.1111/bjh.19238.
    >> Share

  37. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    >> Share

    November 2023
  38. SARTORI G, Tarantelli C, Spriano F, Gaudio E, et al
    The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19218.
    >> Share

  39. WATANABE T, Tobinai K, Wakabayashi M, Maruyama D, et al
    R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
    Br J Haematol. 2023 Nov 23. doi: 10.1111/bjh.19213.
    >> Share

  40. HEINI AD, Bacher U, Pabst T
    Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19195.
    >> Share

  41. CARACCIOLO D, Polera N, Belmonte B, Conforti F, et al
    UMG1/CD3epsilon-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19183.
    >> Share

  42. PEDERSEN MA, Gormsen LC, Jakobsen LH, Eyre TA, et al
    The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
    Br J Haematol. 2023 Nov 13. doi: 10.1111/bjh.19194.
    >> Share

  43. GALLI E, Bellesi S, Pansini I, Di Cesare G, et al
    The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
    Br J Haematol. 2023;203:564-570.
    >> Share

    October 2023
  44. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    >> Share

  45. STUVER R, Noy A, Vardhana SA, Zelenetz AD, et al
    Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19178.
    >> Share

  46. MINSON A, Hamad N, Di Ciaccio P, Talaulikar D, et al
    Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
    Br J Haematol. 2023 Oct 30. doi: 10.1111/bjh.19179.
    >> Share

  47. GONG IY, Prica A, Ante Z, Calzavara A, et al
    Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
    Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166.
    >> Share

  48. RAMSOWER CA, Rosenthal A, Robetorye RS, Mwangi R, et al
    Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19153.
    >> Share

  49. EYRE TA, Bishton MJ, McCulloch R, O'Reilly M, et al
    Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19131.
    >> Share

  50. CALABRETTA E, di Trani M, Corrado F, Sollini M, et al
    Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 18. doi: 10.1111/bjh.19162.
    >> Share

  51. BOYLE S, Roddie C, O'Reilly M, Menne T, et al
    Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
    Br J Haematol. 2023 Oct 17. doi: 10.1111/bjh.19157.
    >> Share

  52. KYVSGAARD ER, Riley C, Clausen MR, Harslof M, et al
    Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy.
    Br J Haematol. 2023 Oct 13. doi: 10.1111/bjh.19156.
    >> Share

  53. MAMLOUK O, Strati P, Feng L, Sun R, et al
    Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19152.
    >> Share

  54. CONTARINI G, Carraro E, Lovisa F, Martire G, et al
    Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19151.
    >> Share

  55. LIU H, He Z, Gui R, Guo J, et al
    Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
    Br J Haematol. 2023 Oct 6. doi: 10.1111/bjh.19140.
    >> Share

  56. GAO J, Dahiya S, Patel SA
    Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Br J Haematol. 2023;203:161-168.
    >> Share

    September 2023
  57. LEWIS KL, Cheah CY
    Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
    Br J Haematol. 2023 Sep 24. doi: 10.1111/bjh.19095.
    >> Share

  58. HAYASHI K, Koyama D, Sato Y, Fukatsu M, et al
    Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19.
    Br J Haematol. 2023 Sep 11. doi: 10.1111/bjh.19106.
    >> Share

  59. LI H, Yuan L, Wang P, Sheng Y, et al
    Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
    Br J Haematol. 2023;202:1055-1060.
    >> Share

  60. PROKOPH N, Matthews JD, Trigg RM, Montes-Mojarro IA, et al
    Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Br J Haematol. 2023;202:985-994.
    >> Share

  61. XIONG J, Zhao WL
    A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma.
    Br J Haematol. 2023 Sep 1. doi: 10.1111/bjh.19066.
    >> Share

    August 2023
  62. ZHANG C, Mou B, Xu J, Wang J, et al
    Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.
    Br J Haematol. 2023 Aug 30. doi: 10.1111/bjh.19089.
    >> Share

  63. GAUTHIER M, Dombrowski D, Vergnolle I, Kfoury E, et al
    Vacuolated lymphocytes as initial presentation of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2023 Aug 23. doi: 10.1111/bjh.19030.
    >> Share

  64. WATANABE M, Kanda J, Fukuda T, Uchida N, et al
    Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
    Br J Haematol. 2023 Aug 23. doi: 10.1111/bjh.19041.
    >> Share

  65. CHUNG EYL, Sartori G, Ponzoni M, Cascione L, et al
    ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
    Br J Haematol. 2023 Aug 16. doi: 10.1111/bjh.19018.
    >> Share

  66. RYAN CE, Zon RL, Redd R, Fisher DC, et al
    Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
    Br J Haematol. 2023 Aug 16. doi: 10.1111/bjh.19037.
    >> Share

  67. ZHOU L, Fu W, Wu S, Xu K, et al
    Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Br J Haematol. 2023;202:517-524.
    >> Share

  68. VITOLO U, Frascione PMM, Bonello F
    Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more?
    Br J Haematol. 2023;202:731-733.
    >> Share

  69. HE MY, Kayamori K
    Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.
    Br J Haematol. 2023;202:720-721.
    >> Share

  70. ROVSING AB, Thomsen EA, Nielsen I, Skov TW, et al
    Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28.
    Br J Haematol. 2023;202:825-839.
    >> Share

    July 2023
  71. JEFFREY A, Mason G, Kerridge I, Kumar P, et al
    Bone marrow pseudo-Gaucher cells demonstrating haemophagocytosis associated with extranodal NK/T cell lymphoma, nasal type.
    Br J Haematol. 2023 Jul 31. doi: 10.1111/bjh.18998.
    >> Share

  72. KUITUNEN H, Puhakka I, Ronka A, Selander T, et al
    Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma.
    Br J Haematol. 2023 Jul 31. doi: 10.1111/bjh.19003.
    >> Share

  73. CARLSEN ED, Aarabi M, Swerdlow SH
    Unexpected MYC::DMD translocation after transformation of follicular lymphoma with IGH::BCL2 and IGH::MYC.
    Br J Haematol. 2023 Jul 23. doi: 10.1111/bjh.18994.
    >> Share

  74. MARTIN GARCIA-SANCHO A, Baile M, Rodriguez G, Dlouhy I, et al
    Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
    Br J Haematol. 2023 Jul 23. doi: 10.1111/bjh.18989.
    >> Share

  75. SULEMAN A, Aktar SJ, Ante Z, Liu N, et al
    Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    Br J Haematol. 2023 Jul 20. doi: 10.1111/bjh.18972.
    >> Share

  76. GAO F, Liu H, Meng X, Liu J, et al
    Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
    Br J Haematol. 2023 Jul 16. doi: 10.1111/bjh.18974.
    >> Share

  77. SHIN J, Lee JY, Lee GW, Kim WS, et al
    Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.
    Br J Haematol. 2023 Jul 5. doi: 10.1111/bjh.18965.
    >> Share

  78. WANG X, Wen L, Liao J, Feng Y, et al
    First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study.
    Br J Haematol. 2023 Jul 2. doi: 10.1111/bjh.18957.
    >> Share

  79. VAN THILLO Q, Dewaele B, De Bie J, Michaux L, et al
    Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion.
    Br J Haematol. 2023;202:e7-e10.
    >> Share

  80. LV M, Liu L, He Y, Yang D, et al
    Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
    Br J Haematol. 2023;202:369-378.
    >> Share

  81. JO T, Yoshihara S, Okuyama Y, Fujii K, et al
    Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
    Br J Haematol. 2023;202:256-266.
    >> Share

  82. LAMURE S, Herbaux C
    Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL.
    Br J Haematol. 2023;202:217-218.
    >> Share

  83. KITAMURA W, Asada N, Naoi Y, Abe M, et al
    Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy.
    Br J Haematol. 2023;202:294-307.
    >> Share

    June 2023
  84. MARTIN GARCIA-SANCHO A, Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, et al
    Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18941.
    >> Share

  85. MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
    Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
    >> Share

  86. WILSON MR, Haynes E, Parsons K, Hopkins D, et al
    'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study.
    Br J Haematol. 2023 Jun 25. doi: 10.1111/bjh.18947.
    >> Share

  87. TURNER R, Quach H, Horvath N, Kerridge I, et al
    Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
    Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
    >> Share

  88. ENTROP JP, Weibull CE, Smedby KE, Jakobsen LH, et al
    Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study.
    Br J Haematol. 2023 Jun 16. doi: 10.1111/bjh.18938.
    >> Share

  89. VUOLIO T, Kuittinen O, Vayrynen JP, Teppo HR, et al
    R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up.
    Br J Haematol. 2023 Jun 6. doi: 10.1111/bjh.18896.
    >> Share

    May 2023
  90. PUCKRIN R, Owen C, Stewart D, Peters A, et al
    Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
    Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.
    >> Share

  91. LIANG JH, Ren YM, Du KX, Gao R, et al
    MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma.
    Br J Haematol. 2023 May 24. doi: 10.1111/bjh.18878.
    >> Share

  92. LAURENT C, Flores M, Chartier L, Huet S, et al
    Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
    Br J Haematol. 2023 May 22. doi: 10.1111/bjh.18881.
    >> Share

  93. STUVER R, Horwitz SM, Advani RH, Vose JM, et al
    Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
    Br J Haematol. 2023 May 22. doi: 10.1111/bjh.18885.
    >> Share

  94. MAROUF A, Molinari N, Sibon D, Cottereau AS, et al
    Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
    Br J Haematol. 2023 May 16. doi: 10.1111/bjh.18859.
    >> Share

  95. DUNS G, Winkle M, Chong L, Ennishi D, et al
    Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma.
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18870.
    >> Share

  96. MCCULLOCH R
    Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18868.
    >> Share

  97. KAMBHAMPATI S, Shumilov E, Saumoy M, Herrera AF, et al
    Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18869.
    >> Share

  98. CHIHARA D, Nastoupil LJ, Flowers CR
    Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives.
    Br J Haematol. 2023 May 11. doi: 10.1111/bjh.18861.
    >> Share

  99. WEI C, Wang W, Zhang Y, Zhao D, et al
    Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
    Br J Haematol. 2023 May 3. doi: 10.1111/bjh.18824.
    >> Share

  100. ATALLAH-YUNES SA, Salman O, Robertson MJ
    Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.
    Br J Haematol. 2023;201:383-395.
    >> Share

  101. NAGLER A, Perriello VM, Falini L, Falini B, et al
    How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Br J Haematol. 2023;201:396-410.
    >> Share

  102. WENNERAS C, Aranburu A, Wass L, Grankvist A, et al
    Infection with Neoehrlichia mikurensis promotes the development of malignant B-cell lymphomas.
    Br J Haematol. 2023;201:480-488.
    >> Share

    April 2023
  103. VOSE JM, Ganguly S, Bierman PJ, Bociek RG, et al
    Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
    Br J Haematol. 2023 Apr 25. doi: 10.1111/bjh.18821.
    >> Share

  104. KUHNL A, Kirkwood AA, Roddie C, Menne T, et al
    CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
    Br J Haematol. 2023 Apr 20. doi: 10.1111/bjh.18810.
    >> Share

  105. DUBNIKOV SHARON T, Assayag M, Avni B, Kfir-Erenfeld S, et al
    Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Apr 18. doi: 10.1111/bjh.18816.
    >> Share

  106. LE GOFF E, Blanc-Durand P, Roulin L, Lafont C, et al
    Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
    Br J Haematol. 2023 Apr 10. doi: 10.1111/bjh.18809.
    >> Share

  107. PUNNETT A, Baxter NN, Hodgson D, Sutradhar R, et al
    Treatment patterns and outcomes in adolescents and young adults with nodular lymphocyte-predominant Hodgkin lymphoma: an IMPACT cohort study.
    Br J Haematol. 2023 Apr 4. doi: 10.1111/bjh.18757.
    >> Share

  108. CAMPBELL BA, Brown R, Lambertini A, Hofman MS, et al
    Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Br J Haematol. 2023 Apr 4. doi: 10.1111/bjh.18644.
    >> Share

  109. BELDI-FERCHIOU A, Jais JP, Ghesquieres H, Casasnovas RO, et al
    Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
    Br J Haematol. 2023;201:256-266.
    >> Share

    March 2023
  110. GAZEAU N, Mitra S, Nudel M, Tilmont R, et al
    Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.
    Br J Haematol. 2023 Mar 31. doi: 10.1111/bjh.18775.
    >> Share

  111. SHEN K, Yang C
    Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.
    >> Share

  112. LANZA F, De Giorgio R, Zavagli G
    The oldest case of lymphoma? Insights from a XIII century fresco.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18750.
    >> Share

  113. WENTZELL S, Morash B, Chang H
    Extensive histiocytosis masking anaplastic large-cell lymphoma (ALCL).
    Br J Haematol. 2023 Mar 23. doi: 10.1111/bjh.18730.
    >> Share

  114. BRAVETTI C, Degaud M, Armand M, Sourdeau E, et al
    Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma.
    Br J Haematol. 2023 Mar 20. doi: 10.1111/bjh.18758.
    >> Share

  115. SHANKAR A, Bomanji J
    An illuminating piece in the jigsaw of Hodgkin lymphoma risk stratification.
    Br J Haematol. 2023 Mar 17. doi: 10.1111/bjh.18764.
    >> Share

  116. MILGROM SA, Kim J, Pei Q, Lee I, et al
    Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18734.
    >> Share

  117. GRUND J, Iben K, Reinke S, Buhnen I, et al
    Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18762.
    >> Share

  118. ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
    Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.
    >> Share

  119. DI CIACCIO PR, Mills G, Shipton MJ, Campbell B, et al
    The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.
    Br J Haematol. 2023 Mar 7. doi: 10.1111/bjh.18727.
    >> Share

  120. LIM KJC, Di Ciaccio P, Polizzotto MN, Milliken S, et al
    Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
    Br J Haematol. 2023 Mar 3. doi: 10.1111/bjh.18704.
    >> Share

    February 2023
  121. BELOT A, Camus V, Portugues C, Paget J, et al
    Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.
    Br J Haematol. 2023 Feb 22. doi: 10.1111/bjh.18705.
    >> Share

  122. WILSON MR, Barrett A, Cheah CY, Eyre TA, et al
    How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Br J Haematol. 2023 Feb 20. doi: 10.1111/bjh.18697.
    >> Share

  123. CHAUBARD S, Marouf A, Lavergne D, Lemonnier F, et al
    Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
    Br J Haematol. 2023 Feb 17. doi: 10.1111/bjh.18689.
    >> Share

  124. ARENA A, Romeo MA, Focaccetti C, Anastasiadou E, et al
    Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma.
    Br J Haematol. 2023 Feb 12. doi: 10.1111/bjh.18688.
    >> Share

  125. OSTROWSKA B, Domanska-Czyz K, Romejko-Jarosinska J, Osowiecki M, et al
    Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
    Br J Haematol. 2023 Feb 10. doi: 10.1111/bjh.18687.
    >> Share

  126. ARCARI A, Tabanelli V, Merli F, Marcheselli L, et al
    Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
    Br J Haematol. 2023 Feb 2. doi: 10.1111/bjh.18678.
    >> Share

  127. CHATTERJEE G, Patkar N
    United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Br J Haematol. 2023;200:277-279.
    >> Share

  128. IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
    Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Br J Haematol. 2023;200:381-384.
    >> Share

  129. QUALLS D, Imber BS, Okwali M, Hamlin PA, et al
    Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
    Br J Haematol. 2023;200:524-527.
    >> Share

    January 2023
  130. DEL TORO-MIJARES R, Oluwole O, Jayani RV, Kassim AA, et al
    Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Br J Haematol. 2023 Jan 29. doi: 10.1111/bjh.18656.
    >> Share

  131. KUNIMI K, Usui Y, Sugawara R, Asakage M, et al
    Clinical features of primary vitreoretinal lymphoma developing extra-central nervous system (CNS)/testicular lymphomas with or without CNS involvement: A single-centre study of 13 cases.
    Br J Haematol. 2023 Jan 24. doi: 10.1111/bjh.18663.
    >> Share

  132. BAGAL B, Sarma R, Dey S, Nayak L, et al
    Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
    Br J Haematol. 2023 Jan 22. doi: 10.1111/bjh.18659.
    >> Share

  133. PUCKRIN R, Chua N, Chin K, Peters A, et al
    Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma.
    Br J Haematol. 2023 Jan 10. doi: 10.1111/bjh.18640.
    >> Share

  134. WILSON J
    Pseudo-faggot cells in splenic marginal zone lymphoma.
    Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.
    >> Share

  135. MORENO DF, Lopez-Guerra M, Paz S, Oliver-Caldes A, et al
    Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia.
    Br J Haematol. 2023;200:187-196.
    >> Share

    December 2022
  136. FIACCADORI V, Neven A, Fortpied C, Aurer I, et al
    Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
    Br J Haematol. 2022 Dec 21. doi: 10.1111/bjh.18594.
    >> Share

  137. SANOU N, Rozen L
    Lymphocytes in monkeypox infection mimicking T-cell lymphoma.
    Br J Haematol. 2022 Dec 16. doi: 10.1111/bjh.18589.
    >> Share

  138. HARMANEN M, Hujo M, Sund R, Sorigue M, et al
    Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
    Br J Haematol. 2022 Dec 13. doi: 10.1111/bjh.18597.
    >> Share

  139. SPRIANO F, Tarantelli C, Arribas AJ, Gaudio E, et al
    In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103.
    Br J Haematol. 2022 Dec 9. doi: 10.1111/bjh.18576.
    >> Share

  140. CHENG CL, Yao CY, Huang PH, Yu CW, et al
    Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
    Br J Haematol. 2022 Dec 8. doi: 10.1111/bjh.18598.
    >> Share

  141. AFIFY Z, Orjuela-Grimm M, Smith CM, Dalal M, et al
    Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
    Br J Haematol. 2022 Dec 1. doi: 10.1111/bjh.18498.
    >> Share

    November 2022
  142. ATMAJA B, Millard T, Wotherspoon A, Attygalle AD, et al
    A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to the eyelid.
    Br J Haematol. 2022 Nov 29. doi: 10.1111/bjh.18573.
    >> Share

  143. CWYNARSKI K, Cummin T, Osborne W, Lewis J, et al
    Management of secondary central nervous system lymphoma.
    Br J Haematol. 2022 Nov 21. doi: 10.1111/bjh.18539.
    >> Share

  144. SHAH H, Jang H, Kim S, Halwani AS, et al
    A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race.
    Br J Haematol. 2022 Nov 18. doi: 10.1111/bjh.18564.
    >> Share

  145. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
    >> Share

  146. SENGAR M, Jain H, Shet T, Sridhar E, et al
    Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
    Br J Haematol. 2022 Nov 2. doi: 10.1111/bjh.18532.
    >> Share

  147. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    >> Share

    October 2022
  148. SAIZ LC, Leache L, Gutierrez-Valencia M, Erviti J, et al
    Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18505.
    >> Share

  149. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18506.
    >> Share

  150. MUNTANOLA A, Mozas P, Mercadal S, Huguet M, et al
    Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18522.
    >> Share

  151. KNORR F, Woessmann W
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18528.
    >> Share

  152. HESS G, Dreyling M, Oberic L, Gine E, et al
    Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
    Br J Haematol. 2022 Oct 18. doi: 10.1111/bjh.18519.
    >> Share

  153. BERTINCHAMP R, Garzaro M, Boutboul D, Galicier L, et al
    Mantle cell lymphoma in human immunodeficiency virus-infected patients.
    Br J Haematol. 2022 Oct 12. doi: 10.1111/bjh.18493.
    >> Share

  154. CHEN M, Ouyang F, Wu T, Hu Y, et al
    Remission of extranodal NK/T-cell lymphoma, nasal type, after SARS-CoV-2 vaccination.
    Br J Haematol. 2022 Oct 5. doi: 10.1111/bjh.18496.
    >> Share

  155. AGARWAL G, Moule S, Cope A, Maudgil D, et al
    Spontaneous splenic rupture as initial presentation of diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Oct 3. doi: 10.1111/bjh.18471.
    >> Share

  156. SMITH OP
    Denis Burkitt: A cancer, the virus and the prevention of man-made diseases.
    Br J Haematol. 2022;199:297.
    >> Share

    September 2022
  157. ZIJTREGTOP EAM, Diez C, Zwaan CM, Veening MA, et al
    Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
    Br J Haematol. 2022 Sep 20. doi: 10.1111/bjh.18473.
    >> Share

  158. GISSELBRECHT C, Sibon D
    Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18468.
    >> Share

  159. FURQAN F, Ahn KW, Chen Y, Kaur M, et al
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18467.
    >> Share

  160. CHERNG HJ, Xu G, Feng L, Steiner R, et al
    Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
    Br J Haematol. 2022 Sep 6. doi: 10.1111/bjh.18441.
    >> Share

  161. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    >> Share

  162. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    >> Share

  163. DHOLARIA B, Mehraban N, Baer B, Long N, et al
    Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
    Br J Haematol. 2022;198:1073-1075.
    >> Share

    August 2022
  164. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    >> Share

  165. LIM SH
    COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18416.
    >> Share

  166. RAJAMAKI A, Hujo M, Sund R, Prusila REI, et al
    Link between disease status at 24 months and mortality in follicular lymphoma.
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18423.
    >> Share

  167. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    >> Share

  168. BINKLEY MS
    Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 22. doi: 10.1111/bjh.18406.
    >> Share

  169. NAIK A, Gooley T, Loeb K, Soma L, et al
    The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment.
    Br J Haematol. 2022 Aug 16. doi: 10.1111/bjh.18404.
    >> Share

  170. JESSA R, Chien N, Villa D, Freeman CL, et al
    Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
    Br J Haematol. 2022 Aug 12. doi: 10.1111/bjh.18399.
    >> Share

  171. STEFFANONI S, Calimeri T, Laurenge A, Fox CP, et al
    Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
    Br J Haematol. 2022 Aug 9. doi: 10.1111/bjh.18396.
    >> Share

  172. TARANTELLI C, Bertoni F
    United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Aug 2. doi: 10.1111/bjh.18384.
    >> Share

  173. ROSLER W, Zenz T
    GOALs in relapsed DLBCL.
    Br J Haematol. 2022;198:419-420.
    >> Share

    July 2022
  174. O'REILLY MA, Sanderson R, Wilson W, Iyengar S, et al
    Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapse
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18378.
    >> Share

  175. WEINSTOCK M, Elavalakanar P, Bright S, Ambati SR, et al
    Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18383.
    >> Share

  176. HARTMANN S, Soltani AS, Bankov K, Bein J, et al
    Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Jul 26. doi: 10.1111/bjh.18376.
    >> Share

  177. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    >> Share

  178. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
    >> Share

  179. DU W, Estalilla OC, Jelic TM, Hayes JD, et al
    Bone marrow involvement by breast implant-associated anaplastic large cell lymphoma.
    Br J Haematol. 2022 Jul 14. doi: 10.1111/bjh.18364.
    >> Share

  180. PICARDI M, Giordano C, Pugliese N, Esposito M, et al
    Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
    Br J Haematol. 2022 Jul 12. doi: 10.1111/bjh.18348.
    >> Share

    June 2022
  181. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18335.
    >> Share

  182. KAWASAKI N, Nishito Y, Yoshimura Y, Yoshiura S, et al
    The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18341.
    >> Share

  183. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    >> Share

  184. MIAN A, Bhattarai N, Sheu M, Ondrejka SL, et al
    Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
    Br J Haematol. 2022 Jun 22. doi: 10.1111/bjh.18333.
    >> Share

  185. KAJI FA, Martinez-Calle N, Sovani V, Fox CP, et al
    Rare central nervous system lymphomas.
    Br J Haematol. 2022;197:662-678.
    >> Share

    May 2022
  186. STRUSSMANN T, Glatzki F, Engelhardt M, Mertelsmann R, et al
    Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.
    Br J Haematol. 2022 May 27. doi: 10.1111/bjh.18280.
    >> Share

  187. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    >> Share

  188. DAWUDI Y, Benali K, Beydon M, Hourseau M, et al
    B-cell lymphoma mimicking relapsing polychondritis.
    Br J Haematol. 2022 May 20. doi: 10.1111/bjh.18220.
    >> Share

  189. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    >> Share

  190. ARMITAGE JO, Gale RP, Jaffe ES
    Lymphoma Nomenclature - What's in a name?
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18063.
    >> Share

  191. MOMOTOW J, Buhnen I, Trautmann-Grill K, Kobbe G, et al
    Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18231.
    >> Share

  192. DITTUS C, Miller JA, Wehbie R, Castillo JJ, et al
    Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
    Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
    >> Share

  193. DIXON JG, Dimier N, Nielsen T, Zheng J, et al
    End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
    >> Share

  194. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    >> Share

    April 2022
  195. KUHNL A, Roddie C, Kirkwood AA, Tholouli E, et al
    A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Br J Haematol. 2022 Apr 29. doi: 10.1111/bjh.18209.
    >> Share

  196. CALABRETTA E, Guidetti A, Ricci F, Di Trani M, et al
    Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18183.
    >> Share

  197. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18197.
    >> Share

  198. TANIGUCHI T, Nakayama S, Tanaka H, Rai S, et al
    Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.
    Br J Haematol. 2022 Apr 22. doi: 10.1111/bjh.18208.
    >> Share

  199. MANSON G, Herbaux C, Schiano JM, Casasnovas O, et al
    Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol. 2022 Apr 21. doi: 10.1111/bjh.18198.
    >> Share

  200. EL-GALALY TC, Glimelius I
    Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
    Br J Haematol. 2022 Apr 19. doi: 10.1111/bjh.18199.
    >> Share

  201. ETHIRAJ P, Sasi B, Holder KN, Lin AP, et al
    Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1alpha intersect to regulate angiogenesis in B-cell lymphoma.
    Br J Haematol. 2022 Apr 12. doi: 10.1111/bjh.18196.
    >> Share

  202. ANDERSEN MD, Hamilton-Dutoit S, Modvig L, Vase M, et al
    Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
    Br J Haematol. 2022 Apr 8. doi: 10.1111/bjh.18180.
    >> Share

  203. EKELS A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, et al
    Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
    Br J Haematol. 2022 Apr 2. doi: 10.1111/bjh.18139.
    >> Share

  204. SHANKAR A, Hall GW, McKay P, Gallop-Evans E, et al
    Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18169.
    >> Share

  205. HESS G, Huttmann A, Witzens-Harig M, Dreyling MH, et al
    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18161.
    >> Share

  206. PASZKIEWICZ-KOZIK E, Michalski W, Taszner M, Mordak-Domagala M, et al
    Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18166.
    >> Share

  207. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    >> Share

  208. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    >> Share

    March 2022
  209. TERAS LR, Bertrand KA, Deubler EL, Chao CR, et al
    Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.
    Br J Haematol. 2022 Mar 29. doi: 10.1111/bjh.18150.
    >> Share

  210. MERCADAL S, Alana M, Barcelo MI, Bruixola G, et al
    Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
    Br J Haematol. 2022 Mar 20. doi: 10.1111/bjh.18148.
    >> Share

  211. GHOLIHA AR, Hollander P, Lof L, Glimelius I, et al
    Checkpoint CD47 expression in classical Hodgkin lymphoma.
    Br J Haematol. 2022 Mar 17. doi: 10.1111/bjh.18137.
    >> Share

  212. BROCKELMANN PJ, Borchmann P
    Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.
    Br J Haematol. 2022 Mar 9. doi: 10.1111/bjh.18130.
    >> Share

  213. RIISE J, Meyer S, Blaas I, Chopra A, et al
    Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination.
    Br J Haematol. 2022 Mar 7. doi: 10.1111/bjh.18149.
    >> Share

  214. EYRE TA, Jensen P, Booth S, El-Galaly TC, et al
    Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.
    Br J Haematol. 2022 Mar 2. doi: 10.1111/bjh.18104.
    >> Share

  215. PALLETT SJC, Wake R, Youngs J, Pope C, et al
    Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
    Br J Haematol. 2022;196:1170-1174.
    >> Share

    February 2022
  216. FOLLOWS GA, Barrington SF, Bhuller KS, Culligan DJ, et al
    Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
    Br J Haematol. 2022 Feb 22. doi: 10.1111/bjh.18083.
    >> Share

  217. ROY I, Smilnak G, Burkart M, Hamilton E, et al
    Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2022 Feb 9. doi: 10.1111/bjh.18054.
    >> Share

  218. SAVANI M, Ahn KW, Chen Y, Ahmed S, et al
    Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
    Br J Haematol. 2022 Feb 2. doi: 10.1111/bjh.18052.
    >> Share

  219. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    >> Share

    January 2022
  220. AVIVI I, Luttwak E, Saiag E, Halperin T, et al
    BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Br J Haematol. 2022 Jan 25. doi: 10.1111/bjh.18029.
    >> Share

  221. EL-GALALY TC, Villa D, Cheah CY, Gormsen LC, et al
    Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Br J Haematol. 2022 Jan 17. doi: 10.1111/bjh.18016.
    >> Share

  222. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    >> Share

  223. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    >> Share

  224. EL-MALLAWANY NK, Curry CV, Allen CE
    Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    Br J Haematol. 2022;196:31-44.
    >> Share

    December 2021
  225. HAEBE S, Keay W, Alig S, Mohr AW, et al
    The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.
    Br J Haematol. 2021 Dec 29. doi: 10.1111/bjh.17990.
    >> Share

  226. REN YM, Shang CY, Liang JH, Yin H, et al
    Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma.
    Br J Haematol. 2021 Dec 28. doi: 10.1111/bjh.18000.
    >> Share

  227. BRANDEFORS L, Sander B, Lundqvist K, Kimby E, et al
    Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Br J Haematol. 2021 Dec 27. doi: 10.1111/bjh.18002.
    >> Share

  228. CHIAPPELLA A, Diop F, Agostinelli C, Novo M, et al
    Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
    Br J Haematol. 2021 Dec 23. doi: 10.1111/bjh.17971.
    >> Share

  229. KREISSL S, Voltin CA, Kaul H, Buhnen I, et al
    Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2021 Dec 20. doi: 10.1111/bjh.17997.
    >> Share

  230. MOLETI ML, Testi AM, Foa R
    Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
    Br J Haematol. 2021 Dec 6. doi: 10.1111/bjh.17979.
    >> Share

    November 2021
  231. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    >> Share

  232. ZHU Y, Tian S, Xu L, Ma Y, et al
    GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study.
    Br J Haematol. 2021 Nov 21. doi: 10.1111/bjh.17960.
    >> Share

  233. GILLESSEN S, Huttmann A, Vucinic V, Muller H, et al
    Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Gro
    Br J Haematol. 2021 Nov 14. doi: 10.1111/bjh.17878.
    >> Share

  234. GUTIERREZ-GARCIA G, Martinez C, Boumendil A, Finel H, et al
    Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17939.
    >> Share

  235. BANERJEE R, Midha S, Kelkar AH, Goodman A, et al
    Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17945.
    >> Share

  236. URBAN R, Chow R, Pickles T, Chan M, et al
    The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma.
    Br J Haematol. 2021 Nov 4. doi: 10.1111/bjh.17684.
    >> Share

  237. LEONCINI L
    Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.
    Br J Haematol. 2021 Nov 2. doi: 10.1111/bjh.17922.
    >> Share

  238. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    >> Share

  239. KAJI D, Kusakabe M, Sakata-Yanagimoto M, Makishima K, et al
    Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
    Br J Haematol. 2021;195:585-594.
    >> Share

  240. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    >> Share

    October 2021
  241. ZHANG S, Zhang T, Liu H, Zhao J, et al
    Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Br J Haematol. 2021 Oct 19. doi: 10.1111/bjh.17894.
    >> Share

  242. HALLIGAN SJ, Grainge MJ, Martinez-Calle N, Fox CP, et al
    Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Br J Haematol. 2021 Oct 18. doi: 10.1111/bjh.17896.
    >> Share

  243. BROCKELMANN PJ
    Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?
    Br J Haematol. 2021 Oct 14. doi: 10.1111/bjh.17891.
    >> Share

  244. MOORE DC, Soni AC, Hu B, Smith ET, et al
    Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Br J Haematol. 2021 Oct 12. doi: 10.1111/bjh.17886.
    >> Share

  245. DLOUHY I, Karube K, Enjuanes A, Salaverria I, et al
    Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17858.
    >> Share

  246. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    >> Share

  247. ZHANG YC, Wang JN, Ma SY, Cai J, et al
    Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 7. doi: 10.1111/bjh.17849.
    >> Share

  248. RICHTER J, John K, Staiger AM, Rosenwald A, et al
    Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
    Br J Haematol. 2021 Oct 6. doi: 10.1111/bjh.17874.
    >> Share

  249. AMAADOR K, Kersten MJ, Visser O, Brink M, et al
    Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2021 Oct 3. doi: 10.1111/bjh.17856.
    >> Share

  250. GUPTA S, Alexander S, Pole JD, Sutradhar R, et al
    Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 1. doi: 10.1111/bjh.17862.
    >> Share

  251. RUDZKI Z, Starczynski J, Dowds J, Pemberton N, et al
    In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.
    Br J Haematol. 2021;195:154.
    >> Share

  252. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    >> Share

    September 2021
  253. TOPP MS, van Meerten T, Houot R, Minnema MC, et al
    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Sep 29. doi: 10.1111/bjh.17673.
    >> Share

  254. RIEDELL PA, Hamadani M, Ahn KW, Litovich C, et al
    Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
    Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865.
    >> Share

  255. LIU W, Chen X, Fan J, Zhu M, et al
    Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Br J Haematol. 2021 Sep 16. doi: 10.1111/bjh.17729.
    >> Share

  256. GERHARD-HARTMANN E, Goergen H, Brockelmann PJ, Mottok A, et al
    9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17793.
    >> Share

  257. BASTIDAS-MORA G, Bea S, Navarro A, Gine E, et al
    Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17815.
    >> Share

  258. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    >> Share

  259. LUTFI F, Holtzman NG, Kansagra AJ, Mustafa Ali M, et al
    The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17738.
    >> Share

  260. BORCHMANN S
    Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17796.
    >> Share

  261. HODSON DJ
    Diffuse large B-cell lymphoma genetics - simplifying the subtyping.
    Br J Haematol. 2021 Sep 7. doi: 10.1111/bjh.17803.
    >> Share

  262. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    >> Share


  263. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    >> Share

    August 2021
  264. MORIN RD, Arthur SE, Hodson DJ
    Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17811.
    >> Share

  265. LADDAGA FE, Masciopinto P, Nardelli C, Vacca MP, et al
    In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy.
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17767.
    >> Share

  266. MARTINEZ-CALLE N, Isbell LK, Cwynarski K, Schorb E, et al
    Advances in treatment of elderly primary central nervous system lymphoma.
    Br J Haematol. 2021 Aug 26. doi: 10.1111/bjh.17799.
    >> Share

  267. FJORDEN K, Ekberg S, Kuric N, Smedby KE, et al
    Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
    Br J Haematol. 2021 Aug 25. doi: 10.1111/bjh.17792.
    >> Share

  268. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Br J Haematol. 2021 Aug 22. doi: 10.1111/bjh.17776.
    >> Share

  269. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    >> Share

  270. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    >> Share

  271. EICHENAUER DA, Buhnen I, Kreissl S, Goergen H, et al
    Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17770.
    >> Share

  272. MISHINA T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, et al
    Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
    Br J Haematol. 2021 Aug 10. doi: 10.1111/bjh.17765.
    >> Share

  273. KESAVAN M, Zammar G, McQuillan JT, Macdonald WBG, et al
    Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17758.
    >> Share

  274. KAJI FA, Martinez-Calle N, Bishton MJ, Figueroa R, et al
    Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17747.
    >> Share

  275. CASTILLO JJ, LaMacchia J, Flynn CA, Sarosiek S, et al
    Plasmablastic lymphoma transformation in a patient with Waldenstrom macroglobulinemia treated with ibrutinib.
    Br J Haematol. 2021 Aug 6. doi: 10.1111/bjh.17759.
    >> Share

  276. LANDSBURG DJ, Barta SK, Ramchandren R, Batlevi C, et al
    Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
    Br J Haematol. 2021 Aug 2. doi: 10.1111/bjh.17730.
    >> Share

  277. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    >> Share

  278. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    >> Share

  279. CORDOBA R, Luminari S, Eyre TA
    The use of frailty assessments in treating older adults with aggressive lymphomas.
    Br J Haematol. 2021;194:677-685.
    >> Share

    July 2021
  280. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    >> Share

  281. LYU R, Wang T, Wang Y, Xiong W, et al
    Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17703.
    >> Share

  282. RINALDI F, Marchesi F, Palombi F, Pelosi A, et al
    MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2021 Jul 28. doi: 10.1111/bjh.17734.
    >> Share

  283. ALCOCEBA M, Garcia-Alvarez M, Chillon MC, Jimenez C, et al
    Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
    Br J Haematol. 2021 Jul 27. doi: 10.1111/bjh.17719.
    >> Share

  284. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    >> Share

  285. OLUWOLE OO, Bouabdallah K, Munoz J, De Guibert S, et al
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17527.
    >> Share

  286. CHAPMAN JR, Bouska AC, Zhang W, Alderuccio JP, et al
    EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Br J Haematol. 2021 Jul 17. doi: 10.1111/bjh.17708.
    >> Share

  287. OHKI K, Kiyokawa N, Watanabe S, Iwafuchi H, et al
    Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
    Br J Haematol. 2021 Jul 13. doi: 10.1111/bjh.17639.
    >> Share

  288. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    >> Share

  289. HARADA T, Iwasaki H, Muta T, Urata S, et al
    Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Br J Haematol. 2021;194:101-110.
    >> Share

    June 2021
  290. BUSSOT L, Chevalier S, Cristante J, Grange B, et al
    Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
    Br J Haematol. 2021 Jun 21. doi: 10.1111/bjh.17550.
    >> Share

  291. YUE LM, Chau D, Kwong YL, Tse E, et al
    Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
    Br J Haematol. 2021 Jun 13. doi: 10.1111/bjh.17581.
    >> Share

  292. SIMA A, Hollander P, Baecklund E, Smedby KE, et al
    Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17577.
    >> Share

  293. KOWA JY, Millard T, Goldman A, Sharma RK, et al
    Are treatment response assessment maps (TRAMs) and (18) F-choline positron emission tomography the future of central nervous system lymphoma imaging?
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17632.
    >> Share

  294. SABATINI PJB, Tremblay-LeMay RMA, Ahmadi Moghaddam P, Delabie JMA, et al
    Marginal zone lymphoma transdifferentiated to histiocytic sarcoma.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17582.
    >> Share

  295. RUMMEL MJ, Janssens A, MacDonald D, Keating MM, et al
    A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Br J Haematol. 2021;193:1123-1133.
    >> Share

  296. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    >> Share

  297. LAKHOTIA R, Roschewski M
    Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Br J Haematol. 2021;193:867-881.
    >> Share

    May 2021
  298. LEE S, Fujita K, Morishita T, Oiwa K, et al
    Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 26. doi: 10.1111/bjh.17554.
    >> Share

  299. GENUARDI E, Romano G, Beccuti M, Alessandria B, et al
    Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Br J Haematol. 2021 May 18. doi: 10.1111/bjh.17519.
    >> Share

  300. SETHI TK, Montanari F, Foss F, Reddy N, et al
    How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome.
    Br J Haematol. 2021 May 14. doi: 10.1111/bjh.17458.
    >> Share

  301. RAMPOTAS A, Wilson MR, Lomas O, Denny N, et al
    Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17513.
    >> Share

  302. HENTRICH M, Muller M, Wyen C, Bogner J, et al
    Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17515.
    >> Share

  303. ABU SABAA A, Morth C, Hasselblom S, Hedstrom G, et al
    Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
    Br J Haematol. 2021 May 5. doi: 10.1111/bjh.17206.
    >> Share

  304. WANG C, Althof PA, Bi C, Zhang W, et al
    A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17255.
    >> Share

  305. BALASUBRAMANIAN S, Wang S, Major C, Hodkinson B, et al
    Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP +/- ibrutinib.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17450.
    >> Share

  306. MA SY, Tian XP, Cai J, Su N, et al
    A prognostic immune risk score for diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17478.
    >> Share

  307. CHIRON D
    Towards ecosystem integration for a better understanding of aggressiveness of B-cell lymphomas.
    Br J Haematol. 2021;193:447-448.
    >> Share

    April 2021
  308. LAPENA-RODRIGUEZ M, Garces-Albir M, Gadea-Mateo R, Mata-Cano D, et al
    Multiple small bowel perforations during the treatment of primary intestinal extranodal natural killer/T-cell lymphoma, nasal type.
    Br J Haematol. 2021 Apr 29. doi: 10.1111/bjh.17229.
    >> Share

  309. HABOT-WILNER Z, Frenkel S, Pe'er J
    Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Br J Haematol. 2021 Apr 26. doi: 10.1111/bjh.17451.
    >> Share

  310. KHURANA A, Maurer MJ
    Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17433.
    >> Share

  311. LOH Z, Salvaris R, Chong G, Churilov L, et al
    Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17436.
    >> Share

  312. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    >> Share

  313. OVERWEEL AFP, Budel LM, Sandberg Y
    Cutaneous blastoid mantle cell lymphoma.
    Br J Haematol. 2021 Apr 5. doi: 10.1111/bjh.17452.
    >> Share

  314. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    >> Share

  315. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    >> Share

  316. POLVERELLI N, Elli EM, Abruzzese E, Palumbo GA, et al
    Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Br J Haematol. 2021;193:356-368.
    >> Share

    March 2021
  317. CONDOM M, Climent F, Fernandez D, Colomer D, et al
    Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience.
    Br J Haematol. 2021;192:1020-1025.
    >> Share

    February 2021
  318. MIKHAEEL NG, Cunningham D, Counsell N, McMillan A, et al
    FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Br J Haematol. 2021;192:504-513.
    >> Share

    January 2021
  319. RODRIGUEZ-PINILLA SM, Domingo-Domenech E, Climent F, Sanchez J, et al
    Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
    Br J Haematol. 2021;192:82-99.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016